Table 2. Markers of Oxidative Stress.

	ODI at 2 weeks (≥4% dips/hour)	MDA (μmol/l)		OxLDL (mU/l)		TAC (nmol/μl)		F2-ISO (ng/ml)		PBMC superoxide generation (RLU/s/cell count)
Control (n=30)		Baseline	2 weeks	Baseline	2 weeks	Baseline	2 weeks	Baseline	2 weeks	Baseline	2 weeks
Mean	3.01	1.43	1.39	11.1	11.6	37.7	38.0	0.77	0.88	0.084	0.089
SD	3.10	0.34	0.31	3.72	4.85	1.71	2.31	0.30	0.42	0.044	0.034
CPAP withdrawal (n=29)		Baseline	2 weeks	Baseline	2 weeks	Baseline	2 weeks	Baseline	2 weeks	Baseline	2 weeks
Mean	45.7	1.36	1.38	13.0	13.2	37.5	37.1	0.81	0.63	0.085	0.082
SD	18.3	0.44	0.47	4.20	5.02	2.37	2.14	0.33	0.26	0.037	0.021
‘Treatment’ effect	+42.8	−0.02		−0.21		−0.77		−0.26		+0.02
95%CIs	+36.0 to +49.5	−0.23 to +0.19		−2.06 to +1.64		−1.96 to +0.43		−0.42 to −0.10		−0.06 to +0.09
P	<0.0001	NS (0.86)		NS (0.82)		NS (0.20)		0.002		NS (0.64)

SD = standard deviation, ODI = overnight oxygen desaturation index (events/hour), CPAP = continuous positive airway pressure, 95%CIs = 95% confidence intervals, MDA = plasma malondialdehyde, OxLDL = plasma oxidised low density lipoproteins, TAC = plasma total antioxidant capacity, F2-ISO = urine F2-isoprostanes, PBMC=peripheral blood mononuclear cells (13 subjects were included in this analysis, control subjects n=7, CPAP withdrawal subjects n=6). RLU=relative light units. ‘Treatment’effect was controlled for the baseline value of the relevant dependent variable, age, BMI, statins, antihypertensives, and smoking status.